News

The phase 2, placebo-controlled, crossover trial will test whether 50 mg once daily lorundrostat may relieve the severity of upper airway obstruction and reduce nocturnal hypertension.

The chief of neuroinfectious diseases and global neurology at Northwestern Medicine discussed a recently published study that highlighted Long COVID’s significant clinical and societal impact. [WATCH TIME: 5 minutes]

In the pivotal phase 3 Clarity AD trial, treatment with a subcutaneous autoinjector of lecanemab led to reduced rates of amyloid-related imaging abnormalities while maintaining similar bioequivalence levels to the original formulation.

The founding director of the Optimal Aging Institute at the NYU Grossman School of Medicine talked about a recent study that estimated the lifetime risk of dementia and its implications for prevention, care, as well as societal planning. [WATCH TIME: 5 minutes]

Eligible participants are ambulatory adults aged 50 or older with mild cognitive impairment or mild Alzheimer disease, confirmed by clinical assessments and a positive amyloid PET scan, and who meet specific health and safety criteria.

Recent research investigated how HSV-1 infection affects tau phosphorylation through the cGAS-STING-TBK1 pathway, highlighting potential new therapeutic strategies for Alzheimer disease.

James Wheless, MD, FAAP, FAAN, FAES, Le Bonheur Chair in Pediatric Neurology at the University of Tennessee Health Science Center, shared insights on his presentation from AES 2024, focusing on stiripentol, an FDA-approved treatment for Dravet syndrome.

A duo of experts from NYU Grossman School of Medicine talked about a new study that identified deficiencies in acetyl-L-carnitine and free carnitine as potential blood biomarkers for Alzheimer disease. [WATCH TIME: 5 minutes]

Using a delayed-start analysis, treatment differences on outcomes of ADAS-Cog13 and ADCS-ADL continued to grow larger during weeks 144 and 192 of the open-label extension.

Here's some of what is coming soon to NeurologyLive® this week.

An ongoing phase 2a study of RAP-219 involves adult patients with drug-resistant epilepsy who have an implanted responsive neurostimulation (RNS) device, allowing for real-time monitoring of intracranial EEG data.

The professor in the department of diagnostic radiology at City of Hope discussed a newly updated published guideline for amyloid and tau PET imaging geared towards improving Alzheimer diagnosis. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on restless legs syndrome.

NeurologyLive® will provide in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

The SORT-IN-2 trial is a Phase 1b/2a proof-of-concept study evaluating the therapeutic potential of VES001, a novel oral treatment designed to target GRN mutations, which are the root cause of frontotemporal dementia.

Neurology News Network. for the week ending January 11, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 10, 2024.

The professor and chair of the Department of Molecular Pathobiology at NYU College of Dentistry provided a clinical overview of preclinical research identifying a new receptor for nerve growth factor that plays an important role in pain signaling. [WATCH TIME: 4 minutes]

Between those infected and uninfected with COVID-19, investigators observed no differences in symptom trajectories, assessed through SymptoMScreen.

The senior vice president of research at The ALS Association discussed the need for standardizing ALS diagnosis across institutions to reduce delays and ensure timely treatment. [WATCH TIME: 4 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Russell Lebovitz, MD, PhD. [LISTEN TIME: 22 minutes]

Results from the open-label phase 1/2 study of tividenofusp alfa demonstrated positive effects on evidence-based surrogate end points in participants with Hunter syndrome.

Masoud Toloue, chief executive officer at Quanterix, and Nicholas J. Ashton, PhD, senior director of the Banner Health Fluid Biomarker Program, discussed the Simoa technology required to test for p-tau217, the expanding understanding of this biomarker, and the next steps for advancing this research.

The primary audience for the new appropriate use criteria is dementia specialists who dedicate a substantial portion of their clinical practice to treating patients with cognitive concerns.

Posdinemab, a monoclonal antibody that targets the mid-domain of Alzheimer disease-specific phosphorylated tau, is currently being investigated in a placebo-controlled phase 2b trial that employs a plasma biomarker as a screening tool.

The revised protocol merges the 6-month symptomatic and 18-month disease-modifying studies into a single trial with a 6-month symptomatic readout and a 12-month disease-modifying evaluation.

In a recent analysis, BrainCheck Access showed a high degree of alignment with the Montreal Cognitive Assessment in differentiating normal cognition, mild cognitive impairment, and dementia.

SGT-212 delivers full-length frataxin via MRI-guided intradentate nucleus infusion and intravenous administration to target mitochondrial dysfunction in neurons and cardiomyocytes, addressing both neurologic and cardiac symptoms.